CHB患儿干扰素α1b长期给药后血清β2-微球蛋白浓度的影响因素分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (982 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the related factors of serum β2-microglobulin concentration after long-term administration of interferon in children with chronic hepatitis B (CHB). Methods Serum samples of 108 children with CHB who were treated at the Fifth Medical Center of People’s Liberation Army General Hospital from December 2017 to September 2019 were collected after long-term interferon α1b application. Multiple linear regression analysis method was used, with serum β2-microglobulin concentration as the dependent variable, taking gender, age, body mass index (BMI), course of treatment, administration time (the interval between sampling time and the last medication before sampling), administration dose, virus genotyping and other information as independent variables, the related influencing factors of serum β2-microglobulin concentration were analyzed. Results There was no correlation between β2-microglobulin and age, course of treatment, time of administration and BMI (P ＞ 0.05). There were no statistically significant differences in different genders, viral hepatitis type B genotypes, and doses of β2-microglobulin (P ＞ 0.05). Dosage, age, time of administration, and course of treatment are related factors that affect the concentration of serum β2-microglobulin (P ＜ 0.05), among them, the serum β2-microglobulin concentration increases with the increase of the dose, and decreases with the increase of age, administration time and treatment course. Conclusion The concentration of serum β2-microglobulin is not only related to the dose, but the time, duration of treatment and age also have certain effects on the concentration of serum β2-microglobulin.

Key words： Children Chronic hepatitis B Interferon β2-microglobulin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHAI Yantao1* WANG Fuchuan2* HOU Jun1 JIA Fan3 LIU Jia4 JIANG Qiyu1 ZHANG Min2▲ BI Jingfeng1▲

Cite this article:

CHAI Yantao1* WANG Fuchuan2* HOU Jun1 JIA Fan3 LIU Jia4 JIANG Qiyu1 ZHANG Min2▲ BI Jingfeng1▲. Influencing factors analysis of β2-microglobulin concentration after long-term interferon α1b administration in children with CHB[J]. 中国医药导报, 2021, 18(23): 60-63,79.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I23/60

[1] 曹林，郭若闻，高月求，等.中西医结合治疗慢性乙型肝炎肝纤维化的研究进展[J].中国医药导报，2019，16（25）：37-40.
[2] 刘沙，马晓北.马晓北教授治疗慢性乙型病毒性肝炎经验介绍[J].中国医药导报，2020，17（21）：169-172.
[3] 池晓玲，萧焕明. 病毒性肝炎防治新形势下对中医药防治肝纤维化的思考[J].临床肝胆病杂志，2018，34（4）：694-697.
[4] Cui F，Shen L，Li L，et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy，China [J]. Emerg Infect Dis，2017，23（5）：765-772.
[5] Liu JF，Yao NJ，Chen TY，et al. Prevalence of mother-to-child transmission of hepatitis B virus：a systematic review and meta-analysis [J]. J Hepatol，2019，70（1）：e123-e124.
[6] 中华医学会感染病学分会，GRADE中国中心.中国乙型肝炎病毒母婴传播防治指南（2019年版）[J].中华传染病杂志，2019，37（7）：388-396.
[7] Indolfi G，Easterbrook P，Dusheiko G，et al. Hepatitis B virus infection in children and adolescents [J]. Lancet Gastroenterol Hepatol，2019，4（6）：466-476.
[8] Terrault NA，Lok ASF，McMahon BJ，et al. Update on prevention，diagnosis，and treatment of chronic hepatitis B：AASLD 2018 hepatitis B guidance [J]. Hepatology，2018， 67（4）：1560-1599.
[9] Bruno R，Sacchi P，Scagnolari C，et al. Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2a in interferon-naive patients with chronic hepatitis C：a randomized，controlled study [J]. Alim Pharmaco Ther，2007， 26（3）：369-376.
[10] Glue P，Fang JW，Rouzier-Panis R，et al. Pegylatedinterferon-alfa2b：Pharmacokinetics，pharmacodynamics，safety and preliminary efficacy data [J]. Clin Pharmacol Ther，2000，68（5）：556-567.
[11] Leede LG JD，Humphries JE，Bechet AC，et al. Novel controlled-released Lemna-derived IFN-alfa 2a（Locteron）：pharmacokinetics，pharmacodynamics and tolerability in a phase I clinical trial [J]. J Interferon Cytokine Res，2008，28（2）：113-122.
[12] Zheng L，Li MP，Gou ZP，et al. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects [J]. Br J Clin Pharmacol，2015，79（4）：650-659.
[13] Sokal，EM，Paganelli M，Wirth S，et al. Management of chronic hepatitis B in childhood：ESPGHAN clinical practice guidelines：consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology，Hepatology and Nutrition [J]. J Hepatol，2013，59（4）：814-829.
[14] Pittatore G，Moggio A，Benedetto C，et al. Endometrial adult/progenitor stem cells：pathogenetic theory and new antiangiogenic approach for endometriosis therapy [J]. Reprod Sci，2014，21（3）：296-304.
[15] 张群生，胡宇才，马文凯，等.慢性心力衰竭患者心脏功能与血清β2微球蛋白水平的关系分析[J].实验与检验医学，2020，38（2）：305-307，325.
[16] 孙景，杨雪梅，李冰.血清β2-微球蛋白与肾病综合征患者肾功能指标、凝血指标的相关性分析[J].血栓与止血学，2021，27（2）：283-284.
[17] 丁子俊，张新华，樊迎朝，等.降钙素原C反应蛋白及β2-微球蛋白检测在新生儿化脓性脑膜炎中的应用价值[J].中国药物与临床，2020，20（5）：731-733.
[18] 王海峰，东淳，李春梦.血清β2-微球蛋白、尿微量白蛋白、尿N-乙酰-β-氨基葡萄糖苷酶联合检测在高血压早期肾损伤诊断中的临床价值[J].陕西医学杂志，2020，49（7）：897-899.
[19] 甘超华，刘洁华.血清β2-微球蛋白和血清胱抑素C水平在高血压肾病早期肾损害中应用[J].数理医药学杂志，2020，33（6）：891-892.
[20] 韩爱芳，刘俊瑾.联合检测血清同型半胱氨酸蛋白酶抑制剂C及 β2-微球蛋白对妊娠糖尿病早期肾损伤的临床价值[J].中国药物与临床，2020，20（20）：3398-3400.
[21] Garcia-Lora A，Algarra I，Garrido F. MHC class Ⅰantigens，immune surveillance，and tumor immune escape [J]. J Cell Physiol，2003，195（3）：346-355.
[22] 邵蔚，石勇铨，王云，等.2型糖尿病视网膜病变患者尿液β2-微球蛋白与血小板/淋巴细胞比值的关系[J].中国老年学杂志，2020，40（14）：2946-2949.
[23] 叶丽红，陈潇楷.β2-微球蛋白联合尿系列蛋白检测在无症状高尿酸血症肾损伤患者诊断中应用及其临床意义[J].检验医学与临床，2020，17（13）：1919-1921.
[24] Nieforth KA，Nadeau R，Patel IH，et al. Use of an indirect pharmacodynamic stimulation model of Mx protein induction to compare in vivo activity of interferon alpha-2a and a polyethylene glycol-modified derivative in healthy subjects [J]. Clin Pharmacol Ther，1996（6）：636-646.
[25] Idrian GG，Ignacio HG，Alina DM，et al. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers [J]. BMC Pharmacol Toxicol，2016，17（1）：58.